TheScreener - Shionogi Co. Ltd. (4507) SHIONOGI sees a downgrade to Neutral on account of less fundamental stars

Report

TheScreener

EUR 14.57 For Business Accounts Only

SHIONOGI sees a downgrade to Neutral on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of SHIONOGI (JP), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title now shows 1 out of 4 stars while market behaviour can be considered defensive. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Neutral. As of the analysis date January 14, 2022, the closing price was JPY 7,489.00 and its target price was estimated at JPY 6,834.79.

15/01/2022 1 EN

Underlying

Shionogi & Co. Ltd.

Shionogi is the parent company of a group engaged in the research and development, purchase, manufacture and sale of pharmaceutical products. Co.'s principal prescription drugs are "Crestor Tablet" for hyperlipidemia treatment, "Irbetan Tablet" for antihypertensive, "Cymbalta Capsule" for treatment for depression and depressive symptoms, "Finibax" and "Finibax Kit" for carbapenem antibiotic, "Differin Gel" for acne vulgaris treatment, "Pirespa Tablet" for idiopathic pulmonary fibrosis treatment, and "OxyContin Tablet" and "OxiNorm Powder" for cancer pain analgesic, and OTC drugs including "Sedes First," "Sedes Hi G," "Pylon," "Rapiacta Bag" and "Rapiacta Vial."

See profile

JP3347200002 Japan

Provider

TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization. theScreener state of art: We provide
theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded.

See profile

Other Reports on these Companies

Pelham Smithers Associates Ltd

PSA Pharma / Healthcare: FY24 Q2 Results for Shionogi, Astellas, DSK

So far this week (as at 31 Oct), it has been a mixed bag of results for several pharma names. Analyst Nia Dokova reviews details of the FY24 Q2 performance at Shionogi, Astellas, Daiichi Sankyo.

October 31, 2024 October 31, 2024 1 EN

Fundamental Research

Pixie Dust Technologies, Inc. Harnessing Sound and Light Waves for Personal Care/Healthcare

Fundamental Research Corp has issued a report entitled “Harnessing Sound and Light Waves for Personal Care/Healthcare – Initiating Coverage” and dated Apr 12, 2024. The full report is now at

EUR 97.15

April 16, 2024 April 16, 2024 1 EN

Hardman & Co

Hardman & Co Monthly: April 2023

Feature article: 2022 Pharma Statistics - 8.7% growth – but worrying signs An efficient reporting system has seen all the listed multinational pharmaceutical companies announcing results for 2022, which has given us the opportunity to update our industry statistics and drug database. This report provides the first snapshot of the global and US rankings of the top 20 drug companies for 2022. 2022 was characterised by 8.7% underlying growth, offset by a large forex impact (-12%), due to USD strength. Much of the growth was driven by antibody-derived drugs and vaccines for treatment and preventi...

April 5, 2023 April 5, 2023 1 EN

AC ENERGY CORP increases its risk exposure and slightly lowers to Neutral

AC ENERGY CORP (PH), a company active in the Alternative Electricity industry, now shows a lower overall rating. The independent financial analyst theScreener confirms the fundamental rating of 4 out of 4 stars. However, the market behaviour deterioration triggered a risk requalification, which can be thus described as moderately risky. theScreener believes that increased risk justifies the general evaluation downgrade to Neutral. As of the analysis date April 8, 2022, the closing price was PHP 8.54 and its expected value was estimated at PHP 8.53.

Free Trial

April 9, 2022 April 9, 2022 1 EN

With a more favourable environment, VUKILE PROPERTY improves to Positive

VUKILE PROPERTY (ZA), a company active in the Real Estate Holding & Development industry, is favoured by a more supportive environment. The independent financial analyst theScreener has confirmed the fundamental rating of the title, which shows 4 out of 4 stars, as well as its unchanged, defensive market behaviour. The title leverages a more favourable environment and raises its general evaluation to Positive. As of the analysis date April 5, 2022, the closing price was ZAR 13.72 and its potential was estimated at ZAR 15.16.

Free Trial

April 6, 2022 April 6, 2022 1 EN

An unfavourable environment weighs on ROYAL BAFOKENG PLATINUM, which sees a downgrade to Slightly Negative

The independent financial analyst theScreener just requalified the general evaluation of ROYAL BAFOKENG PLATINUM (ZA), active in the Platinum & Precious Metals industry. As regards its fundamental valuation, the title still shows 0 out of 4 stars and its market behaviour is seen as moderately risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Slightly Negative. As of the analysis date April 5, 2022, the closing price was ZAR 159.78 and its target price was estimated at ZAR 127.50.

Free Trial

April 6, 2022 April 6, 2022 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

SHIONOGI sees a downgrade to Neutral on account of less fundamental stars

Empowering Investors

PSA Pharma / Healthcare: FY24 Q2 Results for Shionogi, Astellas, DSK

Pixie Dust Technologies, Inc. Harnessing Sound and Light Waves for Personal Care/Healthcare

Hardman & Co Monthly: April 2023

AC ENERGY CORP increases its risk exposure and slightly lowers to Neutral

With a more favourable environment, VUKILE PROPERTY improves to Positive

An unfavourable environment weighs on ROYAL BAFOKENG PLATINUM, which sees a downgrade to Slightly Negative

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe